As a result, PD-L1 IHC is used as an eligibility biomarker in certain cancers (e.g., NSCLC, HNSCC, urothelial carcinoma) but not as an absolute exclusion criterion in others (e.g., melanoma). Here, CD274 is linked to melanoma.